Patents by Inventor Robert Lee Panek

Robert Lee Panek has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • VEGF responsive cell-based assay for determining VEGF bioactivity
    Patent number: 6787323
    Abstract: A VEGF responsive cell-based assay for determining VEGF bioactivity is disclosed. The assay utilizes established signal transduction pathways in a method for determining VEGF bioactivity in a sample.
    Type: Grant
    Filed: February 7, 2002
    Date of Patent: September 7, 2004
    Assignee: Pfizer Inc
    Inventors: Brian Lee Batley, Tawny Kay Dahring, Sotirios K. Karathanasis, Robert Lee Panek, Ye Edward Tian
  • Method for creating endothelial cell dysfunction in cell culture
    Publication number: 20020146679
    Abstract: The proposed invention relates to a method for creating cell culture conditions which causes human endothelial cells in culture when exposed to a cytokine, preferably, TNF&agr; for periods of longer than 5 days (chronic exposure) to become unresponsive to growth factors and other substances in serum. The cell culture assay system allows for screening for novel molecules that may correct endothelial dysfunction and will help identify genes that could be used to prevent or correct endothelial dysfunction with gene therapy.
    Type: Application
    Filed: December 18, 2001
    Publication date: October 10, 2002
    Inventors: Sotirios K. Karathanasis, Zhiwu Lin, Robert Lee Panek
  • VEGF responsive cell-based assay for determining VEGF bioactivity
    Publication number: 20020110830
    Abstract: A VEGF responsive cell-based assay for determining VEGF bioactivity is disclosed. The assay utilizes established signal transduction pathways in a method for determining VEGF bioactivity in a sample.
    Type: Application
    Filed: February 7, 2002
    Publication date: August 15, 2002
    Inventors: Brian Lee Batley, Tawny Kay Dahring, Sotirios K. Karathanasis, Robert Lee Panek, Ye Edward Tian
  • Compounds inhibiting the association of the PDGF receptor and phosphatidylinositol 3-kinase and their use
    Patent number: 6136798
    Abstract: The present invention provides compounds that inhibit the association of platelet-derived growth factor and phosphatidylinositol 3-kinase. The present invention also provides pharmaceutical compositions that contain a compound that inhibits the association of platelet-derived growth factor and phosphatidylinosital 3-kinase, and methods of treating cancer, restenosis, arthritis, dermatitis, atherosclerosis, vein graft intimal hyperplasia, neointimal hyperplasia of vascular smooth muscle and psoriasis using compounds that inhibit the association of platelet-derived growth factor and phosphatidylinositol 3-kinase.
    Type: Grant
    Filed: February 22, 1999
    Date of Patent: October 24, 2000
    Assignee: Warner-Lambert Company
    Inventors: Wayne Livingston Cody, Annette Marian Doherty, Scott R. Eaton, Robert Lee Panek
  • 6-aryl naphthyridines for inhibiting protein tyrosine kinase mediated cellular proliferation
    Patent number: 5952342
    Abstract: 6-Aryl naphthyridines are inhibitors of protein tyrosine kinase, and are thus useful in treating cellular proliferation mediated thereby. The compounds are especially useful in treating atherosclerosis, restenosis, psoriasis, as well as bacterial infections.
    Type: Grant
    Filed: March 18, 1998
    Date of Patent: September 14, 1999
    Assignee: Warner-Lambert Company
    Inventors: Clifton John Blankley, Annette Marian Doherty, James Marino Hamby, Robert Lee Panek, Mel Conrad Schroeder, Howard Daniel Hollis Showalter, Cleo Connolly
  • Pyrido?2, 3-d!pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
    Patent number: 5733914
    Abstract: 6-Aryl pyrido?2,3-d!pyrimidine 7-imines, 7-ones, and 7-thiones are inhibitors of protein tyrosine kinases, and are thus useful in treating cellular proliferation mediated thereby. The compounds are especially useful in treating cancer, atherosclerosis, restenosis, and psoriasis.
    Type: Grant
    Filed: April 3, 1996
    Date of Patent: March 31, 1998
    Assignee: Warner-Lambert Company
    Inventors: Clifton John Blankley, Diane Harris Boschelli, Annette Marian Doherty, James Marino Hamby, Sylvester Klutchko, Robert Lee Panek
  • 6-Aryl pyrido?2,3-d! pyrimidines and naphthyridines for inhibiting protein tyrosine kinase mediated cellular proliferation
    Patent number: 5733913
    Abstract: 6-Aryl pyrido?2,3-d!pyrimidines and naphthyridines are inhibitors of protein tyrosine kinase, and are thus useful in treating cellular proliferation mediated thereby. The compounds are especially useful in treating atherosclerosis, restenosis, psoriasis, as well as bacterial infections.
    Type: Grant
    Filed: November 6, 1995
    Date of Patent: March 31, 1998
    Inventors: Clifton John Blankley, Annette Marian Doherty, James Marino Hamby, Robert Lee Panek, Mel Conrad Schroeder, Howard Daniel Hollis Showalter, Cleo Connolly